Evidence map›Paper›PMID 40002189›Full record

ReviewCancers2025

Alternative Splicing as a Modulator of the Interferon-Gamma Pathway.

Parul Suri, Ariana Badalov, Matteo Ruggiu

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Parul SuriCollege of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway Queens, New York, NY 11439, USA.ORCID 0000-0001-6899-6789
Ariana BadalovLaboratory of RNA Biology and Molecular Neuroscience, Department of Biological Sciences, St. John's University, 8000 Utopia Parkway Queens, New York, NY 11439, USA.
Matteo RuggiuLaboratory of RNA Biology and Molecular Neuroscience, Department of Biological Sciences, St. John's University, 8000 Utopia Parkway Queens, New York, NY 11439, USA.

Funding

Alternative Splicing Modulates the Activity of CaV3.1. an Ion Channel Gene Involved in Spinocerebellar Ataxia, Epilepsy, and Autism Spectrum DisordersR15GM148923 · NIGMS · ST. JOHN'S UNIVERSITY · PI RUGGIU, MATTEO · 2022 to 2024
$680k
NIGMS NIH HHS R15 GM148923NIH/NIGMS 1R15GM148923-01
6 · The paper itself

Abstract

Interferon-gamma (IFN-γ) is a critical cytokine that plays a pivotal role in immune system regulation. It is a key mediator of both cellular defense mechanisms and antitumor immunity. As the sole member of the type II interferon family, IFN-γ modulates immune responses by activating macrophages, enhancing natural killer cell function, and regulating gene expression across multiple cellular processes. Alternative splicing is a post-transcriptional gene expression regulatory mechanism that generates multiple mature messenger RNAs from a single gene, dramatically increasing proteome diversity without the need of a proportional genome expansion. This process occurs in 90-95% of human genes, with alternative splicing events allowing for the production of diverse protein isoforms that can have distinct-or even opposing-functional properties. Alternative splicing plays a crucial role in cancer immunology, potentially generating tumor neoepitopes and modulating immune responses. However, how alternative splicing affects IFN-γ's activity is still poorly understood. This review explores how alternative splicing regulates the expression and function of both upstream regulators and downstream effectors of IFN-γ, revealing complex mechanisms of gene expression and immune response modulation. Key transcription factors and signaling molecules of the IFN-γ pathway are alternatively spliced, and alternative splicing can dramatically alter IFN-γ signaling, immune cell function, and response to environmental cues. Specific splice variants can enhance or inhibit IFN-γ-mediated immune responses, potentially influencing cancer immunotherapy, autoimmune conditions, and infectious disease outcomes. The emerging understanding of these splicing events offers promising therapeutic strategies for manipulating immune responses through targeted molecular interventions.

Indexed as

alternative splicingcancerIFN-γimmunitytherapy

Identifiers

PMID40002189
PMCPMC11853465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.